Pfizer will combine its off-patent drug business with Mylan

The deal will result in Pfizer shareholders owning most of the new company with Mylan's shareholders owning slightly more than 40%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.